Estimaciones de analistas de Wall Street para Larimar Therapeutics, Inc. (LRMR): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 8 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 8 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.39 | ||
| 2026-08-04 | $-0.30 | $-0.38 | +21.4% |
| 2026-05-14 | $-0.31 | $-0.53 | +41.5% |
| 2026-03-19 | $-0.73 | $-0.44 | -65.9% |
| 2025-11-05 | $-0.61 | $-0.39 | -56.4% |
| 2025-08-14 | $-0.41 | $-0.47 | +12.8% |
| 2025-04-30 | $-0.46 | $-0.42 | -9.5% |
| 2025-03-24 | $-0.45 | $-0.29 | -55.2% |
Ratios de valoración
| Precio / Valor contable | 3.23 |
| EV / EBITDA | -1.85 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $212000 | $188000 | $261000 | $78000 | $155000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$212000 | -$188000 | -$261000 | -$78000 | -$155000 | 0 | 0 | 0 | 0 | 0 |
| I+D | $39.8M | $41.7M | $49.5M | $20.8M | $31.3M | $38.4M | $24.2M | $27.7M | $73.3M | $154.2M |
| Generales y Administrativos | $17.1M | $11.9M | $12.9M | $2.4M | $11.4M | $12.1M | $12.3M | $14.1M | $17.6M | $18.3M |
| Gastos Operativos | $56.9M | $53.7M | $62.5M | $23.2M | $42.6M | $50.5M | $36.5M | $41.8M | $90.9M | $172.5M |
| Beneficio Operativo | -$57.1M | -$53.9M | -$62.7M | -$23.2M | -$42.8M | -$50.5M | -$36.5M | -$41.8M | -$90.9M | -$172.5M |
| EBITDA | -$57.4M | -$52.6M | -$60.8M | -$23.1M | -$42.6M | -$50.3M | -$35.0M | -$36.6M | -$80.3M | -$165.3M |
| Gastos por Intereses | $347000 | $971000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$58.2M | -$52.9M | -$63.0M | -$23.1M | -$42.5M | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$165.7M |
| Impuestos | -$300000 | -$900000 | -$1.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$57.9M | -$52.0M | -$61.4M | -$23.1M | -$42.3M | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$165.7M |
| BPA | $-25.44 | $-22.76 | $-22.85 | $-2.51 | $-3.56 | $-2.93 | $-1.33 | $-0.84 | $-1.32 | $-2.27 |
| BPA Diluido | $-25.44 | $-22.76 | $-22.85 | $-2.51 | $-3.56 | $-2.93 | $-1.33 | $-0.84 | $-1.32 | $-2.27 |
| Acciones en Circulación (Diluidas) | $2.3M | $2.3M | $2.7M | $9.2M | $11.9M | $17.2M | $25.8M | $43.9M | $61.3M | $72.9M |
Precio
| Precio | $3.93 |
| Capitalización | $408M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACIU · ALT · AMRN · ANNX · ANRO · DBVT · ENGN
Explorar sector: Healthcare · Biotechnology
Más secciones de LRMR: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones